We are all still active in our own companies, across diverse industries and global markets. We use our experience, knowledge and expertise to bring competitive advantage to your project & company.
ebs works with innovators, entrepreneurs & owners of IP to ensure effective commercialisation of their Intellectual Property.
Alister is an experienced Chair and angel investor. He has been Chair at five successful spinout and startup companies and is currently Chair of a biotech instrument startup. He was previously a founder & Managing Director of an IP commercialisation company which listed 1 year after startup; a founder & VP Sales of an internet video OEM which listed 5 years after startup; and Business Group Manager at an ASIC spin‐out which listed 3 years after he joined.
Gillian has a background in strategic marketing with global brands such as The Royal Bank of Scotland, De La Rue and NCR. She was Director of Commercialisation at ITI Techmedia before becoming an independent commercialisation adviser. She has mentored or coached over 40 spinouts, startups and early stage companies, and has led 2 university technology projects through the spinout process.
For 5 years, Gillian was CEO of Alfacyte Ltd, a therapeutics startup. Before that she was CEO of Quantilyte Ltd., a university spinout developing diagnostic platforms for veterinary applications.
Chris has spent 22 years at the intersection of technology and media. In the games industry since 1996, he has gone from Software Engineer to Chief Technology Officer, working from the smallest indie to the largest game publisher, building both games and the technology that powers them. In 2010, Chris co-founded deltaDNA as a dedicated SaaS Analytics and CRM platform for the games industry. It is now recognised as the premium analytics platform for games and is used across the industry. The company was acquired by Unity Technologies in 2019. Chris is currently part time interim CTO at AdInMo an Ad tech start up based in Edinburgh and Visiting Professor at The University of Abertay.
Dr Caroline Barelle
Caroline is Founder and CEO of a drug discovery company. Elasmogen Ltd is a biotech spinout from The University of Aberdeen, developing a portfolio of novel therapeutic biologics. With postgraduate qualifications in both business and science, Caroline has a strong commercial, partnering and biologics development background. In addition to her role at Elasmogen, Caroline is also an Enterprise and Skills Strategic Board (ESSB) member; Entrepreneur in Residence (Royal Society) for Queen’s University Belfast, UKRI moderator panel member for FLF 2020-22; and a BBSRC review panel member for FoF and SFoF 2020-22.
David has over thirty years of hands on experience working with technology companies from start-ups to multinationals including HSBC, Mondex electronic cash, MasterCard and others. He co-founded a smartcard business, Advanced Smartcard Technologies, and succesfully floated it on the AIM market. The company was subsequently acquired by Trainline where he continued as part of the executive team. David has mentored many technology organisations across a broad range of products and sectors as advisor or non executive director and worked internationally at the highest level.